BioCentury
ARTICLE | Company News

Hemispherx, Swiss Federal Department of Defense, Civil Protection and Sports (DDPS) deal

May 26, 2014 7:00 AM UTC

Hemispherx entered a research deal with the Swiss agency to test Hemispherx's Alferon N Injection against wild-type and Tamiflu oseltamivir-resistant H7N9 influenza virus. DDPS's Swiss Institute for Nuclear, Biological, Chemical Protection will conduct the studies under a data exchange agreement between the Swiss Surgeon General and the U.S. Department of Defense. The parties could not be reached for details.

Last year, Hemispherx presented in vitro data showing Alferon N Injection and Tamiflu each significantly inhibited wild-type H7N9 influenza virus and led to similar reductions in wild-type H7N9 influenza titer after 48 hours of treatment exposure. Hemispherx also said Alferon N Injection significantly inhibited Tamiflu-resistant H7N9 influenza virus (see BioCentury, Sept. 30, 2013). ...